We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+50.68%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$548M
AUM Growth
+$192M
Cap. Flow
+$43.1M
Cap. Flow %
7.87%
Top 10 Hldgs %
43.03%
Holding
102
New
19
Increased
25
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$28M
2
LIAN
LianBio American Depositary Shares
LIAN
+$10.7M
3
NUVL
Nuvalent
NUVL
+$7.74M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.35M
5
ALKS icon
Alkermes
ALKS
+$6.66M

Top Sells

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$10.2M
2
KURA icon
Kura Oncology
KURA
+$6.54M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.41M
4
PRTA icon
Prothena Corp
PRTA
+$3.82M
5
KRYS icon
Krystal Biotech
KRYS
+$3.6M

Sector Composition

Rank Sector Weight
1 Healthcare 86.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$5.88M 1.07%
100,049
+39,623
+66% +$2.23M
ESTA icon
27
CALL
Establishment Labs
ESTA
$2.75B
$5.83M 1.06%
225,000
+85,000
+61% +$2.49M
ALNY icon
28
CALL
Alnylam Pharmaceuticals
ALNY
$36.4B
$5.74M 1.05%
+30,000
New +$5.11M
ROIV icon
29
Roivant Sciences
ROIV
$24.5B
$5.62M 1.03%
500,000
+350,000
+233% +$3.41M
VKTX icon
30
Viking Therapeutics
VKTX
$4.22B
$5.58M 1.02%
300,000
– –
SVRA icon
31
Savara
SVRA
$1.13B
$5.41M 0.99%
1,150,000
– –
CMPS
32
Compass Pathways
CMPS
$1.57B
$4.81M 0.88%
+550,000
New +$3.56M
APLS
33
DELISTED
Apellis Pharmaceuticals
APLS
$4.49M 0.82%
75,000
+35,000
+88% +$1.78M
MLTX icon
34
MoonLake Immunotherapeutics
MLTX
$1.59B
$4.29M 0.78%
70,988
+20,988
+42% +$1.08M
DVAX
35
DELISTED
Dynavax Technologies
DVAX
$4.19M 0.77%
300,000
+100,000
+50% +$1.39M
GPCR icon
36
CALL
Structure Therapeutics
GPCR
$3.34B
$4.08M 0.74%
+100,000
New +$5.73M
AZN icon
37
AstraZeneca
AZN
$255B
$4.04M 0.74%
30,000
– –
AXSM icon
38
Axsome Therapeutics
AXSM
$11.4B
$3.98M 0.73%
+50,000
New +$3.34M
SWTX
39
DELISTED
SpringWorks Therapeutics
SWTX
$3.65M 0.67%
100,000
+58,419
+140% +$1.52M
CRNX icon
40
PUT
Crinetics Pharmaceuticals
CRNX
$8.88B
$3.36M 0.61%
+94,300
New +$2.89M
RLAY icon
41
Relay Therapeutics
RLAY
$4.18B
$3.3M 0.6%
+300,000
New +$2.53M
BBIO icon
42
BridgeBio Pharma
BBIO
$15.8B
$3.23M 0.59%
80,000
+50,000
+167% +$1.5M
KRYS icon
43
Krystal Biotech
KRYS
$10B
$3.1M 0.57%
25,000
-32,500
-57% -$3.6M
CGEM icon
44
Cullinan Oncology
CGEM
$1.08B
$3.06M 0.56%
+300,000
New +$2.66M
TNGX icon
45
Tango Therapeutics
TNGX
$4.48B
$2.97M 0.54%
300,274
-49,726
-14% -$432K
ARGX icon
46
argenx
ARGX
$52.9B
$2.85M 0.52%
+7,500
New +$3.49M
KURA icon
47
Kura Oncology
KURA
$948M
$2.75M 0.5%
191,535
-665,000
-78% -$6.54M
FLNA
48
CALL
Filana Therapeutics
FLNA
$49.3M
$2.72M 0.5%
+121,000
New +$2.56M
EYPT icon
49
EyePoint Inc
EYPT
$1.06B
$2.54M 0.46%
+109,900
New +$1.23M
ASND icon
50
Ascendis Pharma A/S
ASND
$16.5B
$2.52M 0.46%
20,000
-26,400
-57% -$2.63M
1
2
3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Affinity Asset Advisors held 102 positions worth $548M, up 54% from $356M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $43.1M of net new capital in Q4 2023, opening 19 new positions and adding to 25 existing holdings. Its largest new stake was Immunogen Inc: 1,404,608 shares worth $41.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 81% a quarter earlier.

On the sell side, the largest reduction was Apogee Therapeutics, an estimated $10.2M trimmed.

  • Affinity Asset Advisors's largest Q4 2023 buy was Immunogen Inc: 1,404,608 shares worth $41.6M.
  • Affinity Asset Advisors added most to LianBio American Depositary Shares in Q4 2023, an estimated $10.7M increase.
  • Affinity Asset Advisors's biggest Q4 2023 reduction was Apogee Therapeutics, cutting an estimated $10.2M.
  • Affinity Asset Advisors fully exited Prothena Corp in Q4 2023, selling an estimated $3.82M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $548M portfolio in Q4 2023.
  • Affinity Asset Advisors opened 19 new positions and closed 20 in Q4 2023.
  • Affinity Asset Advisors's portfolio value rose 54% quarter-over-quarter to $548M.

Based on Affinity Asset Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.